SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

• Pedro Pérez Segura ^[1] ; Noelia Vilariño Quintela ^[6] ; María Martínez García ^[2] ; Sonia del Barco Berrón ^[3] ; Regina Gironés Sarrió ^[7] ; Jesús García Gómez ^[8] ; Almudena García Castaño ^[4] ; Luis Miguel Navarro Martín ^[5] ; Oscar Gallego Rubio ^[9] ; Estela Pineda Losada ^[10]
  1. [1] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  2. [2] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  3. [3] Hospital Universitari de Girona Dr. Josep Trueta

     Hospital Universitari de Girona Dr. Josep Trueta

     Gerona, España

     
  4. [4] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  5. [5] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  6. [6] Departamento de Oncología Médica, Instituto Catalán de Oncología, Barcelona, España
  7. [7] Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, Valencia, España
  8. [8] Servicio de Oncología Médica, Complejo Hospitalario Universitario de Orense, Orense, España
  9. [9] Servicio de Oncología Médica, Hospital de Sant Pau i La Santa Creu, Barcelona, España
  10. [10] Servicio de Oncología Médica, Hospital Clínic y Genómica Traslacional y Terapias Dirigidas en Tumores Sólidos, IDIBAPS, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2634-2646
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5–10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.